Errector Spinae Plane Block for Postoperative Pain Management in Cardiac Surgery: A Randomized Controlled Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess efficacy of erector spinae plane block (ESP) for postoperative pain management in cardiac surgery patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Erector Spinae Plane Block and Postoperative Recovery After Open-Heart Surgery

NCT07259057

Postoperative Pain Management Open-heart Surgery Median Sternotomy +1 more

COMPLETED NA

Erector Spinae Plane (ESP) Block For Postoperative Pain Management In Lumbar Spine Surgery

NCT03997227

Erector Spinae Block

UNKNOWN NA

Comparison of the Postoperative Analgesic Effectiveness of Erector Spinae Plane Block Versus Its Combination With Superficial Parasternal Intercostal Plane Block Within the ERACS Program

NCT07304635

Sternotomy Postoperative Delirium Postoperative Pain Management

COMPLETED NA

The Effect of Bilateral Erector Spina Plane Block on Postoperative Pain in Adult Cardiac Surgery.

NCT04906239

Postoperative Pain Opioid Use

COMPLETED NA

A Block Method for Pain After Back Surgery

NCT07346599

Nerve Block Postoperative Pain Randomised Clinical Trial

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed about the study and potential risks, all patients giving written informed consent will be randomised (single blind) as block group(patients is performed esp block) and control group. All patients will be evaluate during 48 hours for postoperative pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erector Spinae Plane Block Cardiac Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

esp block group

Group Type EXPERIMENTAL

erector spinae plane block

Intervention Type PROCEDURE

ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.

iv analgesia

Intervention Type DRUG

iv contromal

control group

Group Type ACTIVE_COMPARATOR

iv analgesia

Intervention Type DRUG

iv contromal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erector spinae plane block

ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.

Intervention Type PROCEDURE

iv analgesia

iv contromal

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be ASA score I-III
* Must be 18-75 years old
* must undergo cardiac surgery

Exclusion Criteria

* emergency surgery,
* bleeding diathesis,
* presence of contraindications to LA agents used in this study,
* use of chronic opioids,
* psychiatric disorders.
* prolonged extubation
* presence of infection at the injection site.
* cardiovascular conditions (EF\<40, LMCA obstruction)

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No